Immunic (IMUX) to Release Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is projected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 12:30 PM ET.

Immunic (NASDAQ:IMUX) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.18). On average, analysts expect Immunic to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Immunic Trading Down 5.1%

IMUX stock traded down $0.58 during trading on Wednesday, reaching $10.70. The stock had a trading volume of 250,590 shares, compared to its average volume of 340,448. Immunic has a 1-year low of $5.06 and a 1-year high of $15.10. The company has a market capitalization of $145.73 million, a P/E ratio of -1.53 and a beta of 1.20. The firm has a fifty day moving average price of $11.10 and a 200 day moving average price of $8.42.

Wall Street Analysts Forecast Growth

IMUX has been the topic of a number of recent analyst reports. Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a report on Monday. Stifel Nicolaus set a $25.00 price objective on shares of Immunic and gave the stock a “buy” rating in a report on Thursday, April 16th. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Guggenheim initiated coverage on shares of Immunic in a report on Tuesday, March 24th. They issued a “buy” rating and a $70.00 price objective on the stock. Finally, upgraded shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $52.43.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently modified their holdings of IMUX. Qube Research & Technologies Ltd acquired a new stake in shares of Immunic during the third quarter worth $29,000. Two Sigma Investments LP acquired a new stake in shares of Immunic during the third quarter worth $52,000. Virtu Financial LLC acquired a new stake in shares of Immunic during the third quarter worth $99,000. XTX Topco Ltd acquired a new stake in shares of Immunic during the fourth quarter worth $120,000. Finally, Jane Street Group LLC raised its holdings in shares of Immunic by 46.8% during the fourth quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock worth $153,000 after purchasing an additional 91,346 shares during the period. 51.82% of the stock is owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.